Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1988 1
1991 1
1993 1
1994 1
1995 3
1997 2
1998 1
1999 7
2000 12
2001 18
2002 5
2003 6
2004 3
2005 5
2006 3
2007 6
2008 10
2009 10
2010 10
2011 17
2012 10
2013 17
2014 18
2015 26
2016 30
2017 25
2018 12
2019 18
2020 34
2021 30
2022 52
2023 44
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Results by year

Filters applied: . Clear all
Page 1
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.
Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM; VX19-147-101 Study Group. Egbuna O, et al. Among authors: ojo a. N Engl J Med. 2023 Mar 16;388(11):969-979. doi: 10.1056/NEJMoa2202396. N Engl J Med. 2023. PMID: 36920755 Clinical Trial.
Conversion Weights.
Ojo A, Patel P, Boehning AP. Ojo A, et al. 2023 Mar 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Mar 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 32491540 Free Books & Documents.
Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis.
Mariani LH, Eddy S, AlAkwaa FM, McCown PJ, Harder JL, Nair V, Eichinger F, Martini S, Ademola AD, Boima V, Reich HN, El Saghir J, Godfrey B, Ju W, Tanner EC, Vega-Warner V, Wys NL, Adler SG, Appel GB, Athavale A, Atkinson MA, Bagnasco SM, Barisoni L, Brown E, Cattran DC, Coppock GM, Dell KM, Derebail VK, Fervenza FC, Fornoni A, Gadegbeku CA, Gibson KL, Greenbaum LA, Hingorani SR, Hladunewich MA, Hodgin JB, Hogan MC, Holzman LB, Jefferson JA, Kaskel FJ, Kopp JB, Lafayette RA, Lemley KV, Lieske JC, Lin JJ, Menon R, Meyers KE, Nachman PH, Nast CC, O'Shaughnessy MM, Otto EA, Reidy KJ, Sambandam KK, Sedor JR, Sethna CB, Singer P, Srivastava T, Tran CL, Tuttle KR, Vento SM, Wang CS, Ojo AO, Adu D, Gipson DS, Trachtman H, Kretzler M. Mariani LH, et al. Among authors: ojo ao. Kidney Int. 2023 Mar;103(3):565-579. doi: 10.1016/j.kint.2022.10.023. Epub 2022 Nov 25. Kidney Int. 2023. PMID: 36442540 Free PMC article.
Novel Risk Factors for Progression of Diabetic and Nondiabetic CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.
Anderson AH, Xie D, Wang X, Baudier RL, Orlandi P, Appel LJ, Dember LM, He J, Kusek JW, Lash JP, Navaneethan SD, Ojo A, Rahman M, Roy J, Scialla JJ, Sondheimer JH, Steigerwalt SP, Wilson FP, Wolf M, Feldman HI; CRIC Study Investigators. Anderson AH, et al. Among authors: ojo a. Am J Kidney Dis. 2021 Jan;77(1):56-73.e1. doi: 10.1053/j.ajkd.2020.07.011. Epub 2020 Aug 28. Am J Kidney Dis. 2021. PMID: 32866540 Free PMC article. Clinical Trial.
Immunological aspect on late allograft dysfunction.
Sun Q, Ojo AO, Li XC. Sun Q, et al. Among authors: ojo ao. J Immunol Res. 2014;2014:625031. doi: 10.1155/2014/625031. Epub 2014 Apr 14. J Immunol Res. 2014. PMID: 24834436 Free PMC article. No abstract available.
Cardiac Resynchronization Therapy for Heart Failure.
Ojo A, Tariq S, Harikrishnan P, Iwai S, Jacobson JT. Ojo A, et al. Interv Cardiol Clin. 2017 Jul;6(3):417-426. doi: 10.1016/j.iccl.2017.03.010. Epub 2017 Apr 26. Interv Cardiol Clin. 2017. PMID: 28600094 Review.
Reproductive Justice: A Case-Based, Interactive Curriculum.
Ojo A, Singer MR, Morales B, Merz AA, Molina RL, Pelletier A, Carmen A, Moreno MA, Lopez-Carmen VA, Ye SY, Starosta A, Rowley J, Yin SH, Amanuel H, Radford CC, Schwartz LN, Wijangco I, Jowell AR, Schaefer KM, Potter J, Mateo CM, Bartz D. Ojo A, et al. MedEdPORTAL. 2022 Oct 25;18:11275. doi: 10.15766/mep_2374-8265.11275. eCollection 2022. MedEdPORTAL. 2022. PMID: 36310568 Free PMC article.
Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.
Ojo AS, Akinyemi O, Araoye MO, Ali A. Ojo AS, et al. Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e27-e40. doi: 10.1016/j.clml.2022.10.009. Epub 2022 Oct 23. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36402701 Review.
394 results